6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00058838 (ClinicalTrials.gov)	April 2003	14/4/2003	Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease	A Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease.	Parkinson Disease	Drug: sumanirole	Pfizer	NULL	Completed	30 Years	N/A	Both	854	Phase 3	United States;Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain
2	NCT00036218 (ClinicalTrials.gov)	December 2001	8/5/2002	Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.	A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.	Parkinson Disease	Drug: sumanirole;Drug: ropinirole	Pfizer	NULL	Completed	30 Years	N/A	Both	600	Phase 3	United States;Argentina;Mexico;Puerto Rico
3	NCT00036205 (ClinicalTrials.gov)	August 2000	8/5/2002	Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease	Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.	Parkinson Disease	Drug: sumanirole	Pfizer	NULL	Terminated	30 Years	N/A	Both	984	Phase 3	United States;Argentina;Colombia;Puerto Rico